Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 495Neoplasms 301Breast Neoplasms 298Colorectal Neoplasms 229Neoplasm Metastasis 194Prostatic Neoplasms 174Ovarian Neoplasms 173Multiple Myeloma 158Lung Neoplasms 157Recurrence 134Melanoma 121Pancreatic Neoplasms 116Squamous Cell Carcinoma of Head and Neck 105Stomach Neoplasms 101Leukemia, Myeloid, Acute 101Endometrial Neoplasms 101Small Cell Lung Carcinoma 88Leukemia, Lymphocytic, Chronic, B-Cell 86Triple Negative Breast Neoplasms 85Lymphoma, Non-Hodgkin 85Carcinoma, Renal Cell 82Carcinoma, Hepatocellular 79Urinary Bladder Neoplasms 77Lymphoma, Large B-Cell, Diffuse 74Lymphoma, Follicular 67Advanced Solid Tumors 66Parkinson Disease 4, Autosomal Dominant Lewy Body 62Lymphoma 61Glioblastoma 58Head and Neck Neoplasms 56

Interventions

luspatercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × beta-Thalassemia × 90 days × Clear all
NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting
665 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡